Breaking News
January 22, 2018 - Specially prepared supplement helps women to run faster, study shows
January 22, 2018 - 3-D Stent Retriever with Aspiration Proves Mettle in AIS
January 22, 2018 - Public health research seeks to understand how natural disasters impact spread of Zika
January 22, 2018 - Research reveals role of nanophenomenon in stimulating bone-repair process
January 22, 2018 - Epilepsy associated with volume and thickness differences in brain matter
January 22, 2018 - Trevena Announces FDA Acceptance for Review of New Drug Application for Olinvo (oliceridine) Injection
January 22, 2018 - A Noteworthy Margin of Error
January 22, 2018 - Firm advances human trials of revolutionary vaccine
January 22, 2018 - Many Indians put away treating orthopedic problems
January 22, 2018 - Cherwell releases new pocket guide to prepared culture media
January 22, 2018 - Huron earns ISO 13485 certification for quality management system
January 22, 2018 - Avion Pharmaceuticals Announces FDA Approval of Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) Oral Contraceptive
January 22, 2018 - Multi-Gene Test For Early CVD; Neighborhood HF Risk; Novel Testosterone Drugs
January 22, 2018 - Skipping breakfast disrupts ‘clock genes’ that regulate body weight
January 22, 2018 - Creativity May Rely on ‘Teamwork’ in the Brain
January 22, 2018 - NeuroBreak: Alzheimer’s Germ Contest; High Salt Diet May Be Bad for Brain
January 22, 2018 - Diabetics may often fare poorly in hospice care
January 22, 2018 - Performance enhancing benefits of caffeine more apparent for infrequent tea, coffee drinkers
January 22, 2018 - HHS Unveils Framework for Interoperability
January 22, 2018 - More dentists to discuss risks of HPV-related cancers with their patients
January 21, 2018 - Research shows how Zika virus damages placenta to cause malformations in babies
January 21, 2018 - Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
January 21, 2018 - Drug Allergies: Time to Re-Test?
January 21, 2018 - Mitochondrial protein in cardiac muscle cells linked to heart failure, study finds
January 21, 2018 - Women more likely than men to die from a heart attack
January 21, 2018 - Next generation genomic sequencing can help detect pathogens after joint replacement
January 21, 2018 - Gov’t Shutdown Looms as Senate Debates Spending Bill
January 21, 2018 - Emergency Readiness for Older Adults and People with Disabilities
January 21, 2018 - Heart health at risk for Latinas over worries about deportation
January 21, 2018 - Scientists methodically identify genes related to blood feeding and non-biting mosquitoes
January 21, 2018 - Researchers discover potential target genes to halt thyroid cancer progression
January 21, 2018 - Youth with shared residency after parents’ divorce have less mental issues
January 21, 2018 - Sleep Better, Lose Weight? – Drugs.com MedNews
January 21, 2018 - More $$ Needed for Health Emergencies, Senators Told
January 21, 2018 - Gene test to predict breast cancer recurrence less cost effective in real world practice
January 21, 2018 - Study finds rise in number of adolescents receiving psychiatric or neurodevelopmental diagnosis
January 21, 2018 - Reminders can improve immunization rates
January 21, 2018 - A More Personalized Approach to PSA Screening in 2017
January 21, 2018 - T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma
January 21, 2018 - Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
January 21, 2018 - Have Robotics Had a Detrimental Effect on Surgical Residency?
January 21, 2018 - Being bilingual may help autistic children
January 21, 2018 - Metrics Are Not Widespread in Rheumatoid Care
January 21, 2018 - Neuroanatomic abnormalities ID’d in those at risk for autism
January 21, 2018 - Children born with Down’s syndrome have superior genome that compensates for disability
January 21, 2018 - Study finds higher risks for asymptomatic paroxysmal AF patients
January 21, 2018 - The Second Stage of Diet Resolutions
January 21, 2018 - CT Scans Reduce Lung Cancer Deaths … But Among Whom?
January 21, 2018 - ADHD drug use soars among young women
January 21, 2018 - Researchers propose new regulation mechanism linked to action of SirT6 on chromatin
January 21, 2018 - Statins appear to reduce risk of repeated surgery in patients who undergo vitrectomy
January 21, 2018 - Morning Break: Hep A Outbreak Spreads; Tide Pod Challenge; Keeping Lobsters Out of Hot Water
January 21, 2018 - EULAR and ACR present SLE classification criteria at the 2017 ACR/ARHP Annual Meeting
January 21, 2018 - Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
January 21, 2018 - House Passes Funding Bill with 6-Year CHIP Renewal
January 21, 2018 - DASH ranked Best Diet Overall for eighth year in a row by U.S. News and World Report
January 21, 2018 - Dementia study sheds light on how damage spreads through brain
January 20, 2018 - Morning Break: Missing Maria Deaths; N.J. Doc Charged in Wife’s Murder; Viva Vaseline!
January 20, 2018 - No interventions proven to prevent late-life dementia
January 20, 2018 - Judge orders new Olympus trial over superbug death
January 20, 2018 - Don’t Rely on Just One Blood Pressure Test for Kids: Study
January 20, 2018 - Going Off the Deep End About Water
January 20, 2018 - Parental attention can reduce risk of drug abuse in adolescence
January 20, 2018 - Mast Uri System offers efficient and cost-friendly diagnostic solution
January 20, 2018 - International SOS, Chatham House sign partnership agreement to further advance Global Health Security Agenda
January 20, 2018 - Study offers way to predict onset of lung disease in children with cystic fibrosis
January 20, 2018 - C-Suite Must Lead in Ending Sexual Harassment
January 20, 2018 - Researchers find a way to ‘starve’ cancer
January 20, 2018 - Applied math can help predict genesis and evolution of different cancers
January 20, 2018 - UCLA researchers describe herpes virus structure associated with Kaposi’s sarcoma
January 20, 2018 - New study enrolls first patient to evaluate potential of WaveCrest LAAO System
January 20, 2018 - New review explores effects of exposing developing brains to general anesthesia
January 20, 2018 - GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
January 20, 2018 - Weight-Loss Surgery Approaches Offer Similar Results
January 20, 2018 - Free online access to millions of documents on chemical toxicity
January 20, 2018 - CE marked MAST Toxoreagent kit for detection of Toxoplasma antibodies
January 20, 2018 - DNA study sheds light on longstanding puzzle of cell division
January 20, 2018 - Montefiore provides specialized medical care to parents of adopted children
January 20, 2018 - Enzyme discovery provides new horizon of therapeutic opportunities across disease spectrum
January 20, 2018 - New smartphone app successfully enables remote monitoring of surgical wounds
Huntington’s disease drug clears initial hurdles

Huntington’s disease drug clears initial hurdles

image_pdfDownload PDFimage_print

Huntington’s disease is a genetic disorder that affects the brain progressively and has no known cure till date. In a breakthrough, the first drug that can target and reduce the cause behind this dreaded disease has been found to be effective, safe and well tolerated in a human clinical trial that was conducted by UCL scientists.

The protein associated with the disease is called huntingtin protein and this drug successfully lowered the levels of this protein and reduced the harm caused to the nervous system.

The new drug IONIS-HTTRx has been in the pipeline for over ten years now being tried on laboratory animals and in the labs. This was the first human trial that was conducted with the new drug. The trial began in the last months of 2015 and was led by Professor Sarah Tabrizi UCL Institute of Neurology, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator. It was supported by Ionis Pharmaceuticals.

The trial involved 46 patients with early Huntington’s disease in 9 different study centres spanning across United Kingdom, Germany and Canada making it a multi-centric trial. These patients were divided into two groups – one to receive the test drug and the other to receive placebo. The patients were given four doses of the new drug or placebo that was injected into the spinal fluid of the patient so that it reached the brain.

As the trial progressed, this dose was raised to change the design into an ascending dose trial design. At every step patient safety and well being was assessed along with the effectiveness of the drug.

At the end of the trail this week, the researchers announced that the drug was deemed safe and well tolerated among the human participants. According to Professor Tabrizi, “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”

The trial was to assess the safety as well as a the effectiveness of the new drug. Huntingtin protein levels are markers of this disease. The team used an ultra sensitive assay to measure the concentrations of the protein in the patient’s spinal fluid both before and after treatment. They found that IONIS-HTTRx­ could successfully lower the levels of the mutant huntingtin.

With this significant success, Ionis’ partner, Roche now would license IONIS-HTTRx and take further responsibility for the development, regulatory approval and final marketing of the drug. Ionis has announced that all the patients who were part of this pilot trial would not be part of an extension of the trial to receive IONIS-HTTRx.

The results of the present trial are being prepared to be presented at scientific meetings and published in scientific journals. The study was supported by The National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre

Huntington’s disease typically starts in the 30s or 50s and worsens with time. If one parent has this disease, the chances of the child getting it are 50 percent. At present around 10,000 people in UK and 30,000 people in America are living with Huntington’s disease. There is a problem at the genetic level especially at the huntingtin gene that codes for the huntingtin protein. This huntingtin protein is necessary for the normal development of the brain cells.

Reference: https://www.ucl.ac.uk/news/news-articles/1217/111217-huntingtons-disease-protein

Tagged with:

About author

Related Articles